Capital Reduction / Redemption / Conversion

Windlas Biotech proposes to buy back 4,70,000 equity shares (2.23% of capital) at ₹1,000 per share via tender offer, aggregating ₹47 crore. The buyback offers a 31-33% premium to historical VWAPs and